Theranos Inc. is appointing two new executives to head regulatory and compliance efforts, the company said Thursday. The company has also created a compliance and quality committee to oversee the efforts. Dave Wurtz, previously a senior director of compliance at ThermoFisher Scientific, was named vice president, regulatory and quality, and Daniel Guggenheim, previously an assistant general counsel for regulatory law at McKesson Corp., was named chief compliance officer. Both will report to Elizabeth Holmes, the chief executive officer. The appointments come after U.S. regulators have banned Holmes from operating a medical laboratory for at least two years after issues with blood testing at Theranos.
Copyright © 2016 MarketWatch, Inc.
Continue Reading Below